Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Cushing's syndrome (CS) is a severe condition that results from chronic exposure to elevated circulating cortisol levels; it is a rare but potentially life-threating condition, especially when not timely diagnosed and treated. Even though the diagnosis can be straightforward in florid cases due to their typical phenotype, milder forms can be missed. Despite the availability of different screening tests, the diagnosis remains challenging as none of the available tools proved to be fully accurate. Due to the ubiquitous effect of cortisol, it is easy understandable that its excess leads to a variety of systemic complications including hypertension, metabolic syndrome, bone damages and neurocognitive impairment. This article discusses clinical presentation of CS with an eye on the most frequent cortisol-related comorbidities and discuss the main pitfalls of first- and second-line tests in endogenous hypercortisolism diagnostic workup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Glucocorticoid-Induced Skeletal Muscle Atrophy
Schakman, O., Kalista, S., Barbé, C., Loumaye, A., & Thissen, J. P. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.036 · Cited by 705
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Research works printed but not linked: 174
- Miljic, 2012, Pathogenesis of vascular complications in Cushing's syndrome, Horm Athens Greece, 11, 21, 10.1007/BF03401535 · DOI
- Lindholm, 2001, Incidence and late prognosis of cushing's syndrome: a population-based study, J Clin Endocrinol Metab, 86, 117
- Boscaro, 2009, Approach to the patient with possible Cushing's syndrome, J Clin Endocrinol Metab, 94, 3121, 10.1210/jc.2009-0612 · DOI · Paper page
- Ragnarsson, 2019, The incidence of Cushing's disease: a nationwide Swedish study, Pituitary, 22, 179, 10.1007/s11102-019-00951-1 · DOI · Paper page
- Tirosh, 2018, Genetics of micronodular adrenal hyperplasia and Carney complex, Presse Medicale Paris Fr 1983, 47, e127
- Lodish, 2018, Cushing's syndrome in pediatrics: an update, Endocrinol Metab Clin N Am, 47, 451, 10.1016/j.ecl.2018.02.008 · DOI · Paper page
- Lacroix, 2015, Cushing's syndrome, Lancet Lond Engl, 386, 913, 10.1016/S0140-6736(14)61375-1 · DOI · Paper page
- Monteiro, 2019, Adrenal carcinoma IN children: longitudinal study IN minas gerais, Brazil, Rev Paul Pediatr Orgao Of Soc Pediatr Sao Paulo, 37, 20, 10.1590/1984-0462/;2019;37;1;00002 · DOI
- Nieman, 2015, Cushing's Syndrome: update on signs, symptoms and biochemical screening, Eur J Endocrinol Eur Fed Endocr Soc, 173, 10.1530/EJE-15-0464 · DOI · Paper page
- Storr, 2007, Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances, Trends Endocrinol Metab TEM, 18, 167, 10.1016/j.tem.2007.03.005 · DOI
- Barbot, 2019, The pathophysiology and treatment of hypertension in patients with cushing's syndrome, Front Endocrinol, 10, 321, 10.3389/fendo.2019.00321 · DOI
- Davi, 2017, Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study, Eur J Endocrinol, 176, 453, 10.1530/EJE-16-0809 · DOI
- Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinol Metab, 84, 2664
- Akaza, 2010, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing's syndrome, Endocr J, 57, 245, 10.1507/endocrj.K09E-260 · DOI
- Fallo, 2009, Cardiovascular autonomic function in Cushing's syndrome, J Endocrinol Invest, 32, 41, 10.1007/BF03345677 · DOI
- Takagi, 2009, Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome, Endocr J, 56, 1009, 10.1507/endocrj.K09E-198 · DOI
- Carrasco, 2012, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system, Endocrine, 41, 487, 10.1007/s12020-012-9597-z · DOI · Paper page
- Petersenn, 2014, High variability in baseline urinary free cortisol values in patients with Cushing's disease, Clin Endocrinol, 80, 261, 10.1111/cen.12259 · DOI · Paper page
- Dekker, 2012, The effect of common genetic variation in 11β-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression, J Clin Endocrinol Metab, 97, E233, 10.1210/jc.2011-0601 · DOI · Paper page
- DeRijk, 2006, A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness, J Clin Endocrinol Metab, 91, 5083, 10.1210/jc.2006-0915 · DOI · Paper page
- Løvås, 2009, Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone, Eur J Endocrinol, 160, 993, 10.1530/EJE-08-0880 · DOI · Paper page
- Martinez, 2009, Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population, Am J Hypertens, 22, 649, 10.1038/ajh.2009.39 · DOI
- Ragnarsson, 2014, Common genetic variants in the glucocorticoid receptor and the 11β-hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing's syndrome in remission, J Clin Endocrinol Metab, 99, E1803, 10.1210/jc.2014-1906 · DOI · Paper page
- Valassi, 2017, A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome, Clin Endocrinol, 87, 433, 10.1111/cen.13414 · DOI
- Boscaro, 2001, Cushing's syndrome, Lancet Lond Engl, 357, 783, 10.1016/S0140-6736(00)04172-6 · DOI · Paper page
- Bansal, 2015, Pitfalls in the diagnosis and management of Cushing's syndrome, Neurosurg Focus, 38, E4, 10.3171/2014.11.FOCUS14704 · DOI · Paper page
- Ceccato, 2015, Screening tests for cushing's syndrome: urinary free cortisol role measured by LC-MS/MS, J Clin Endocrinol Metab, 100, 3856, 10.1210/jc.2015-2507 · DOI · Paper page
- Alexandraki, 2009, The prevalence and characteristic features of cyclicity and variability in Cushing's disease, Eur J Endocrinol, 160, 1011, 10.1530/EJE-09-0046 · DOI · Paper page
- Atkinson, 2011, What is the best approach to suspected cyclical Cushing syndrome? Strategies for managing Cushing's syndrome with variable laboratory data, Clin Endocrinol, 75, 27, 10.1111/j.1365-2265.2011.04033.x · DOI · Paper page
- Boscaro, 2000, The diagnosis of Cushing's syndrome: atypical presentations and laboratory shortcomings, Arch Intern Med, 160, 3045, 10.1001/archinte.160.20.3045 · DOI · Paper page
- Meikle, 2003, Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography, J Clin Endocrinol Metab, 88, 3521, 10.1210/jc.2003-030234 · DOI · Paper page
- Turpeinen, 1997, Determination of urinary free cortisol by HPLC, Clin Chem, 43, 1386, 10.1093/clinchem/43.8.1386 · DOI · Paper page
- Ceccato, 2014, The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice, Eur J Endocrinol, 171, 1, 10.1530/EJE-14-0061 · DOI · Paper page
- Aranda, 2016, Accuracy of immunoassay and mass spectrometry urinary free cortisol in the diagnosis of Cushing's syndrome, Pituitary, 19, 496, 10.1007/s11102-016-0730-5 · DOI
- Pappachan, 2017, Cushing's syndrome: a practical approach to diagnosis and differential diagnoses, J Clin Pathol, 70, 350, 10.1136/jclinpath-2016-203933 · DOI · Paper page
- Raff, 1998, Late-night salivary cortisol as a screening test for Cushing's syndrome, J Clin Endocrinol Metab, 83, 2681
- Raff, 2012, Cushing's syndrome: diagnosis and surveillance using salivary cortisol, Pituitary, 15, 64, 10.1007/s11102-011-0333-0 · DOI
- Graham, 2013, A comparison of the use of urinary cortisol to creatinine ratios and nocturnal salivary cortisol in the evaluation of cyclicity in patients with Cushing's syndrome, J Clin Endocrinol Metab, 98, E72, 10.1210/jc.2012-2925 · DOI · Paper page
- Chiodini, 2017, Six controversial issues on subclinical Cushing's syndrome, Endocrine, 56, 262, 10.1007/s12020-016-1017-3 · DOI
- Masjkur, 2019, Plasma steroid profiles in subclinical compared with overt adrenal cushing syndrome, J Clin Endocrinol Metab, 104, 4331, 10.1210/jc.2018-02349 · DOI · Paper page
- Terzolo, 2011, AME position statement on adrenal incidentaloma, Eur J Endocrinol, 164, 851, 10.1530/EJE-10-1147 · DOI · Paper page
- Talbot, 2003, Analytical and clinical aspects of adrenocorticotrophin determination, Ann Clin Biochem, 40, 453, 10.1258/000456303322326371 · DOI · Paper page
- Barbot, 2016, Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome, Pituitary, 19, 488, 10.1007/s11102-016-0729-y · DOI
- Newell-Price, 2002, Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome, J Clin Endocrinol Metab, 87, 1640
- Nieman, 1993, A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 77, 1308
- Ritzel, 2015, ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test, Eur J Endocrinol, 173, 197, 10.1530/EJE-14-0912 · DOI · Paper page
- al-Saadi, 1998, A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome, Clin Endocrinol, 48, 45, 10.1046/j.1365-2265.1998.00345.x · DOI
- Aron, 1997, Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 82, 1780
- Avgerinos, 1994, The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison, Ann Intern Med, 121, 318, 10.7326/0003-4819-121-5-199409010-00002 · DOI · Paper page
- Aytug, 2012, Assessment of the utility of the high-dose dexamethasone suppression test in confirming the diagnosis of Cushing disease, Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol, 18, 152
- Bruno, 1985, Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome, Acta Endocrinol, 109, 158
- Dichek, 1994, A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 78, 418, 10.1210/jcem.78.2.8106630 · doi:10.1210/jcem.78.2.8106630 · Paper page
- Flack, 1992, Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome, Ann Intern Med, 116, 211, 10.7326/0003-4819-116-3-211 · DOI · Paper page
- Grossman, 1988, CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test, Clin Endocrinol, 29, 167, 10.1111/j.1365-2265.1988.tb00258.x · DOI · Paper page
- Hermus, 1986, The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome, Lancet Lond Engl, 2, 540, 10.1016/S0140-6736(86)90113-3 · DOI
- Liddle, 1960, Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 20, 1539, 10.1210/jcem-20-12-1539 · DOI · Paper page
- Midgette, 1995, High-dose dexamethasone suppression testing versus inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a decision analysis, Am J Med Sci, 309, 162, 10.1097/00000441-199503000-00007 · DOI
- Rossi, 1996, [Night suppression with high doses of dexamethasone and metyrapone tests for the etiological diagnosis of Cushing syndrome], Medicina, 56, 455
- Sriussadaporn, 1996, Nocturnal 8 mg dexamethasone suppression test: a practical and accurate test for identification of the cause of endogenous Cushing's syndrome, Br J Clin Pract, 50, 9, 10.1111/j.1742-1241.1996.tb10010.x · DOI
- Tyrrell, 1986, An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome, Ann Intern Med, 104, 180, 10.7326/0003-4819-104-2-180 · DOI · Paper page
- van den Bogaert, 1999, The continuous 7-hour intravenous dexamethasone suppression test in the differential diagnosis of ACTH-dependent Cushing's syndrome, Clin Endocrinol, 51, 193, 10.1046/j.1365-2265.1999.00759.x · DOI
- Vilar, 2007, [Endogenous Cushing's syndrome: clinical and laboratorial features in 73 cases], Arq Bras Endocrinol Metabol, 51, 566, 10.1590/S0004-27302007000400010 · DOI
- Isidori, 2003, Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 88, 5299, 10.1210/jc.2003-030510 · DOI · Paper page
- Nieman, 1986, The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome, Ann Intern Med, 105, 862, 10.7326/0003-4819-105-6-862 · DOI · Paper page
- Tsagarakis, 2002, The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion, J Clin Endocrinol Metab, 87, 1646
- Kola, 2008, Dynamic testing in Cushing's syndrome, Pituitary, 11, 155, 10.1007/s11102-007-0079-x · DOI
- Colombo, 1994, MR of corticotropin-secreting pituitary microadenomas, AJNR Am J Neuroradiol, 15, 1591
- Vitale, 2017, Pituitary magnetic resonance imaging in Cushing's disease, Endocrine, 55, 691, 10.1007/s12020-016-1038-y · DOI
- Chowdhury, 2010, A change in pituitary magnetic resonance imaging protocol detects ACTH-secreting tumours in patients with previously negative results, Clin Endocrinol, 72, 502, 10.1111/j.1365-2265.2009.03646.x · DOI · Paper page
- Erickson, 2010, 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing's syndrome, Clin Endocrinol, 72, 793, 10.1111/j.1365-2265.2009.03723.x · DOI
- Fukuhara, 2019, Outcomes of three-Tesla magnetic resonance imaging for the identification of pituitary adenoma in patients with Cushing's disease, Endocr J, 66, 259, 10.1507/endocrj.EJ18-0458 · DOI
- Grober, 2018, Comparison of MRI techniques for detecting microadenomas in Cushing's disease, J Neurosurg, 128, 1051
- Kasaliwal, 2013, Volume interpolated 3D-spoiled gradient echo sequence is better than dynamic contrast spin echo sequence for MRI detection of corticotropin secreting pituitary microadenomas, Clin Endocrinol, 78, 825, 10.1111/cen.12069 · DOI · Paper page
- Tabarin, 1998, Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease, Clin Endocrinol, 49, 293, 10.1046/j.1365-2265.1998.00541.x · DOI · Paper page
- Cristante, 2019, Why we should still treat by neurosurgery patients with Cushing's disease and a normal or inconclusive pituitary MRI, J Clin Endocrinol Metab, 10.1210/jc.2019-00333 · DOI · Paper page
- Losa, 2019, Bilateral inferior petrosal sinus sampling in adrenocorticotropin-dependent hypercortisolism: always, never, or sometimes?, J Endocrinol Invest, 10.1007/s40618-019-1006-5 · DOI
- Findling, 2004, Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent, J Clin Endocrinol Metab, 89, 6005, 10.1210/jc.2004-1378 · DOI · Paper page
- Bonelli, 1999, Venous subarachnoid hemorrhage after inferior petrosal sinus sampling for adrenocorticotropic hormone, AJNR Am J Neuroradiol, 20, 306
- Lefournier, 1999, One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 84, 3401
- Obuobie, 2000, Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease, J Endocrinol Invest, 23, 542, 10.1007/BF03343772 · DOI
- Castinetti, 2007, Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome, Eur J Endocrinol, 157, 271, 10.1530/EJE-07-0215 · DOI · Paper page
- Tsagarakis, 2007, J Clin Endocrinol Metab, 92, 10.1210/jc.2006-2691 · DOI · Paper page
- Chen, 2019, The effects of sampling lateralization on bilateral inferior petrosal sinus sampling and desmopressin stimulation test for pediatric Cushing's disease, Endocrine, 63, 582, 10.1007/s12020-018-1779-x · DOI
- Deipolyi, 2017, Bilateral inferior petrosal sinus sampling: experience in 327 patients, J Neurointerventional Surg, 9, 196, 10.1136/neurintsurg-2015-012164 · DOI
- Feng, 2018, Tumour lateralization in Cushing's disease by inferior petrosal sinus sampling with desmopressin, Clin Endocrinol, 88, 251, 10.1111/cen.13505 · DOI
- Pereira, 2019, Diagnostic accuracy of bilateral inferior petrosal sinus sampling: the experience of a tertiary centre, Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc
- Wind, 2013, The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease, J Clin Endocrinol Metab, 98, 2285, 10.1210/jc.2012-3943 · DOI · Paper page
- Isidori, 2015, The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications, J Hypertens, 33, 44, 10.1097/HJH.0000000000000415 · DOI · Paper page
- Isidori, 2015, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect, Eur J Endocrinol, 173, R101, 10.1530/EJE-15-0308 · DOI
- Pivonello, 2016, Complications of Cushing's syndrome: state of the art, Lancet Diabetes Endocrinol, 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
- Magiakou, 1997, Blood pressure in children and adolescents with Cushing's syndrome before and after surgical care, J Clin Endocrinol Metab, 82, 1734
- Pecori Giraldi, 2007, Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure, Horm Metab Res Horm Stoffwechselforschung Horm Metab, 39, 908, 10.1055/s-2007-992813 · DOI
- Magiakou, 2006, Hypertension in Cushing's syndrome, Best Pract Res Clin Endocrinol Metabol, 20, 467, 10.1016/j.beem.2006.07.006 · DOI
- Kirilov, 2003, Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome, Eur J Endocrinol, 149, 549, 10.1530/eje.0.1490549 · DOI · Paper page
- Kelly, 2000, Role of erythropoietin in cortisol-induced hypertension, J Hum Hypertens, 14, 195, 10.1038/sj.jhh.1000959 · DOI
- Pirpiris, 1992, Pressor responsiveness in corticosteroid-induced hypertension in humans, Hypertens Dallas Tex 1979, 19, 567
- Wallerath, 1999, Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension, Proc Natl Acad Sci U S A, 96, 13357, 10.1073/pnas.96.23.13357 · DOI · Paper page
- Kamenický, 2014, Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study, J Clin Endocrinol Metab, 99, E2144, 10.1210/jc.2014-1783 · DOI · Paper page
- Muiesan, 2003, Left ventricular structural and functional characteristics in Cushing's syndrome, J Am Coll Cardiol, 41, 2275, 10.1016/S0735-1097(03)00493-5 · DOI · Paper page
- Toja, 2012, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure, Clin Endocrinol, 76, 332, 10.1111/j.1365-2265.2011.04206.x · DOI
- Ainscough, 2009, Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction, Cardiovasc Res, 81, 592, 10.1093/cvr/cvn230 · DOI
- Brilla, 1992, Mineralocorticoid excess, dietary sodium, and myocardial fibrosis, J Lab Clin Med, 120, 893
- Pecori Giraldi, 2011, High prevalence of prolonged QT interval duration in male patients with Cushing's disease, Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc, 119, 221, 10.1055/s-0031-1271628 · DOI
- Chandran, 2013, Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism, Neuroendocrinology, 97, 309, 10.1159/000345905 · DOI
- Albiger, 2006, Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors, Horm Metab Res Horm Stoffwechselforschung Horm Metab, 38, 405, 10.1055/s-2006-944545 · DOI
- Baykan, 2007, Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome, Endocrine, 31, 300, 10.1007/s12020-007-0033-8 · DOI
- Duprez, 2006, Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review, J Hypertens, 24, 983, 10.1097/01.hjh.0000226182.60321.69 · DOI · Paper page
- Rizzoni, 2006, Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism, J Clin Endocrinol Metab, 91, 2638, 10.1210/jc.2006-0101 · DOI · Paper page
- Barahona, 2013, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome, J Clin Endocrinol Metab, 98, 1093, 10.1210/jc.2012-3547 · DOI · Paper page
- Neary, 2013, Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography, J Clin Endocrinol Metab, 98, 2045, 10.1210/jc.2012-3754 · DOI · Paper page
- Debono, 2016, Cushing's syndrome: where and how to find it, Front Horm Res, 46, 15, 10.1159/000443861 · DOI
- Ferraù, 2018, Metabolic syndrome in cushing's syndrome patients, Front Horm Res, 49, 85, 10.1159/000486002 · DOI
- Geer, 2012, Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI, J Clin Endocrinol Metab, 97, 1702, 10.1210/jc.2011-3123 · DOI · Paper page
- Geer, 2010, MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease, Clin Endocrinol, 73, 469, 10.1111/j.1365-2265.2010.03829.x · DOI
- Berthon, 2014, A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans, Nutr Res Newsl N, 34, 179, 10.1016/j.nutres.2013.12.006 · DOI
- Castonguay, 1991, Glucocorticoids as modulators in the control of feeding, Brain Res Bull, 27, 423, 10.1016/0361-9230(91)90136-8 · DOI
- Tataranni, 1996, Effects of glucocorticoids on energy metabolism and food intake in humans, Am J Physiol, 271, E317
- Pivonello, 2014, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clin Endocrinol, 81, 408, 10.1111/cen.12431 · DOI · Paper page
- Pivonello, 2009, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery, J Clin Endocrinol Metab, 94, 223, 10.1210/jc.2008-1533 · DOI · Paper page
- Friedman, 1996, Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM, Endocr J, 43, 645, 10.1507/endocrj.43.645 · DOI · Paper page
- Barbot, 2018, Diabetes mellitus secondary to cushing's disease, Front Endocrinol, 9, 284, 10.3389/fendo.2018.00284 · DOI · Paper page
- Bodine, 2015, Glucocorticoids and skeletal muscle, Adv Exp Med Biol, 872, 145, 10.1007/978-1-4939-2895-8_7 · DOI · Paper page
- Kuo, 2013, Metabolic functions of glucocorticoid receptor in skeletal muscle, Mol Cell Endocrinol, 380, 79, 10.1016/j.mce.2013.03.003 · DOI · Paper page
- Eriksen, 2015, Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance, Diabetologia, 58, 920, 10.1007/s00125-015-3522-y · DOI
- Brennan-Speranza, 2012, Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism, J Clin Invest, 122, 4172, 10.1172/JCI63377 · DOI · Paper page
- Oldknow, 2015, Endocrine role of bone: recent and emerging perspectives beyond osteocalcin, J Endocrinol, 225, R1, 10.1530/JOE-14-0584 · DOI · Paper page
- Bernal-Mizrachi, 2007, An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension, Cell Metabol, 5, 91, 10.1016/j.cmet.2006.12.010 · DOI
- Yi, 2012, Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity, Diabetes, 61, 339, 10.2337/db11-1239 · DOI · Paper page
- Geelen, 2013, BclI glucocorticoid receptor polymorphism is associated with greater body fatness: the Hoorn and CODAM studies, J Clin Endocrinol Metab, 98, E595, 10.1210/jc.2012-3442 · DOI · Paper page
- Moreira, 2013, Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's disease, Clin Sao Paulo Braz, 68, 579, 10.6061/clinics/2013(05)01 · DOI
- Webb, 2010, Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma, J Clin Endocrinol Metab, 95, 630, 10.1210/jc.2009-0806 · DOI · Paper page
- Jeffcoate, 1977, Metyrapone in long-term management of Cushing's disease, Br Med J, 2, 215, 10.1136/bmj.2.6081.215 · DOI · Paper page
- Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J Clin Endocrinol Metab, 98, 3446, 10.1210/jc.2013-1771 · DOI · Paper page
- Munir, 2010, Management of diabetes mellitus in Cushing's syndrome, Neuroendocrinology, 92, 82, 10.1159/000314316 · DOI · Paper page
- Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients, J Clin Endocrinol Metab, 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
- Trementino, 2010, Coagulopathy in Cushing's syndrome, Neuroendocrinology, 92, 55, 10.1159/000314349 · DOI · Paper page
- Koutroumpi, 2014, Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?, Pituitary, 17, 68, 10.1007/s11102-013-0467-3 · DOI
- Zilio, 2016, A venous thromboembolism risk assessment model for patients with Cushing's syndrome, Endocrine, 52, 322, 10.1007/s12020-015-0665-z · DOI
- Barbot, 2015, Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing?, Pituitary, 18, 487, 10.1007/s11102-014-0600-y · DOI
- Erem, 2009, Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels, J Endocrinol Invest, 32, 169, 10.1007/BF03345709 · DOI
- Patrassi, 1992, The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state, Blood Coagul Fibrinolysis Int J Haemost Thromb, 3, 789, 10.1097/00001721-199212000-00013 · DOI · Paper page
- Kastelan, 2009, Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers, Endocrine, 36, 70, 10.1007/s12020-009-9186-y · DOI
- Manetti, 2010, Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery, Eur J Endocrinol, 163, 783, 10.1530/EJE-10-0583 · DOI · Paper page
- Casonato, 1999, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome, Blood Coagul Fibrinolysis Int J Haemost Thromb, 10, 145, 10.1097/00001721-199904000-00006 · DOI · Paper page
- Barbot, 2018, Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease, Endocrine, 62, 207, 10.1007/s12020-018-1669-2 · DOI
- van der Pas, 2012, The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy, J Clin Endocrinol Metab, 97, 1303, 10.1210/jc.2011-2753 · DOI · Paper page
- Kaltsas, 2002, Osteoporosis in Cushing's syndrome, Front Horm Res, 30, 60, 10.1159/000061073 · DOI
- Manelli, 2000, Glucocorticoid-induced osteoporosis, Trends Endocrinol Metab TEM, 11, 79, 10.1016/S1043-2760(00)00234-4 · DOI
- Minetto, 2004, Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, 15, 855, 10.1007/s00198-004-1616-3 · DOI
- Tauchmanovà, 2006, Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status, J Clin Endocrinol Metab, 91, 1779, 10.1210/jc.2005-0582 · DOI · Paper page
- Di Somma, 2002, Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease, Clin Endocrinol, 56, 153, 10.1046/j.0300-0664.2001.01454.doc.x · DOI · Paper page
- Canalis, 2001, Glucocorticoid-induced osteoporosis: summary of a workshop, J Clin Endocrinol Metab, 86, 5681, 10.1210/jcem.86.12.8066 · DOI · Paper page
- Seibel, 2013, Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives, Lancet Diabetes Endocrinol, 1, 59, 10.1016/S2213-8587(13)70045-7 · DOI · Paper page
- Weinstein, 2011, Clinical practice. Glucocorticoid-induced bone disease, N Engl J Med, 365, 62, 10.1056/NEJMcp1012926 · DOI · Paper page
- Rubin, 2002, Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence, J Clin Endocrinol Metab, 87, 4033, 10.1210/jc.2002-012101 · DOI · Paper page
- Di Somma, 1998, Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease, Clin Endocrinol, 48, 655, 10.1046/j.1365-2265.1998.00486.x · DOI · Paper page
- Lane, 2000, Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial, J Bone Miner Res Off J Am Soc Bone Miner Res, 15, 944, 10.1359/jbmr.2000.15.5.944 · DOI · Paper page
- Scillitani, 2014, Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, 25, 441, 10.1007/s00198-013-2588-y · DOI · Paper page
- Kristo, 2006, Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study, Eur J Endocrinol, 154, 109, 10.1530/eje.1.02067 · DOI · Paper page
- Pivonello, 2015, Neuropsychiatric disorders in Cushing's syndrome, Front Neurosci, 9, 129, 10.3389/fnins.2015.00129 · DOI · Paper page
- Sonino, 2001, Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment, CNS Drugs, 15, 361, 10.2165/00023210-200115050-00003 · DOI · Paper page
- Jeffcoate, 1979, Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol, Q J Med, 48, 465
- Bourdeau, 2002, Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism, J Clin Endocrinol Metab, 87
- Forget, 2002, Persistent cognitive impairment following surgical treatment of Cushing's syndrome, Psychoneuroendocrinology, 27, 367, 10.1016/S0306-4530(01)00059-2 · DOI
- Bleicken, 2010, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency, Clin Endocrinol, 72, 297, 10.1111/j.1365-2265.2009.03596.x · DOI · Paper page
- Minetto, 2011, Steroid myopathy: some unresolved issues, J Endocrinol Invest, 34, 370, 10.1007/BF03347462 · DOI
- Wajchenberg, 1995, Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease, J Clin Endocrinol Metab, 80, 2791
- Minetto, 2011, Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease, Eur J Endocrinol, 164, 985, 10.1530/EJE-10-1169 · DOI
- Pereira, 2011, Glucocorticoid-induced myopathy, Jt Bone Spine Rev Rhum, 78, 41, 10.1016/j.jbspin.2010.02.025 · DOI · Paper page
- Arnaldi, 2012, Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications, J Endocrinol Invest, 35, 434, 10.1007/BF03345431 · DOI
- Valassi, 2019, High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry, Eur J Endocrinol, 181, 461, 10.1530/EJE-19-0464 · DOI · Paper page
- Ilias, 2005, Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health, J Clin Endocrinol Metab, 90, 4955, 10.1210/jc.2004-2527 · DOI · Paper page
- Sarlis, 2000, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin, J Clin Endocrinol Metab, 85, 42
- Critchley, 2018, Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study, Diabetes Care, 41, 2127, 10.2337/dc18-0287 · DOI · Paper page
Cited by
Approach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
Tabarin, A., Assié, G., Barat, P., Bonnet, F., Bonneville, J. F., Borson-Chazot, F., Bouligand, J., Boulin, A., Brue, T., Caron, P., et al. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.02.001 · Cited by 59
Kannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa107 · Cited by 36
“Neoplastic hypercortisolism is often responsible for cardiometabolic problems, including obesity, diabetes, hypertension, and low bone density, as well as significant neurocognitive and neuropsychiatric challenges [1-16].”
Background
Metadata
- Authors
- Barbot, M., Zilio, M., & Scaroni, C.
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 34
- Issue
- 2
- Pages
- 101380
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W3003229257
- Cited by
- 116
- References
- 57
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. https://app.cochat.ai/papers/10.1016/j.beem.2020.101380
- The paper
- Barbot, M., Zilio, M., & Scaroni, C. (2020). Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. Best Practice & Research Clinical Endocrinology & Metabolism. https://doi.org/10.1016/j.beem.2020.101380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.